Clinical Trial Detail

NCT ID NCT04370509
Title Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

renal cell carcinoma

Therapies

Pembrolizumab

Axitinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.